# A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

> **NCT00768339** · PHASE1,PHASE2 · TERMINATED · sponsor: **Aegera Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, B-Cell

## Interventions

- **DRUG:** AEG35156 antisense IV infusion

## Key facts

- **NCT ID:** NCT00768339
- **Lead sponsor:** Aegera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-06
- **Final completion:** 2011-09
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2011-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768339, "A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00768339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*